Epirus Biopharmaceuticals and mAbxience sign Latin America distribution deal for infliximab biosimilar

May 18, 2015 12:07 PM

Epirus Biopharmaceuticals, Inc. and mAbxience, entered into a development and future distribution deal for Epirus’ lead program, BOW015 (infliximab). 

The agreement will be for the Latin American markets, including Argentina, Chile, Ecuador, Paraguay, Uruguay and Venezuela.

mAbxience is a wholly-owned subsidiary of CHEMO Group, a well-established global healthcare corporation. CHEMO Group generates over $1 billion in annual revenues with 5,000 professionals across 40 countries.

Leveraging the CHEMO Group’s infrastructure, mAbxience will be responsible for regulatory submissions, using BOW015’s existing data package, and eventual commercialization in these select Latin American markets.

“We are pleased to work with a strong regional partner to register and commercialize our infliximab biosimilar,” stated Amit Munshi, president and chief executive officer, EPIRUS Biopharmaceuticals. “We are committed to improving patient access to biosimilars globally and believe mAbxience has the right focus and infrastructure in these markets to advance this important medicine.”

“This is an exciting development for both companies. We are confident in our ability to execute and advance BOW015, given the high quality of the existing data package and our expertise within these regions,” said Carlos Bañado, chief executive officer, mAbxience.

Source: Epirus Biopharmaceuticals press release

Leave a Reply

Twitter ID
(ID only. No links or "@" symbols)

Latest News on Biosimilar News

Share an Article?

Writing an article is not only a great way to share your knowledge, but it is also a great way to give back to the community.

We value all our contributors and if you have a website, we will surely give a link back to your site and products.
Wanna contribute?


Biosimilar News was started for the people who are interested in this rapidly growing business area. So if you have suggestions or feedback on how we can improve, please let us know. If you want to see a specific topic covered, answer to a specific question, or anything else of this sort, just write us. We do our best to keep up!
Make a suggestion now!